Form 4: Shattuck Labs CFO Boosts Stake in Private Placement

Shattuck Labs' Chief Financial Officer, Andrew R. Neill, acquired 64,027 shares of common stock and accompanying warrants in a private placement.

Summary

• Andrew R. Neill, Chief Financial Officer of Shattuck Labs, Inc. (STTK), participated in a private placement that closed on August 25, 2025.
• Neill acquired 64,027 shares of the Issuer's common stock and 64,027 accompanying warrants to purchase common stock.
• The combined price paid for each share and accompanying warrant was $0.8677.
• The warrants are exercisable at a price of $1.0846 per share.
• Following this transaction, Neill directly beneficially owns 237,473 shares of common stock and 64,027 warrants.
• The warrants become exercisable from their original issuance date until 30 days after the public announcement of Phase 1 clinical trial data for SL-325 (including receptor occupancy and safety) and the design of planned Phase 2 clinical trials.

Sentiment

Score: 7

Explanation: The insider purchase by the CFO, especially in a private placement, indicates management confidence and aligns interests. While the warrant exercise is tied to clinical trial success, this is typical for biotech. The capital raise itself is a positive for funding operations.

Positives

• The Chief Financial Officer's participation in the private placement demonstrates strong insider confidence in Shattuck Labs' future prospects.
• Increased insider ownership aligns management's financial interests more closely with those of public shareholders.
• The private placement provided capital to Shattuck Labs, supporting its ongoing operations and clinical development.

Negatives

• The value of the acquired securities, particularly the warrants, is highly dependent on the successful outcome and public announcement of data from the Phase 1 clinical trial of SL-325 and the design of planned Phase 2 clinical trial(s), introducing significant R&D risk.

Risks

• The exercisability and value of the warrants are contingent upon the successful completion and public disclosure of specific data from the Phase 1 clinical trial of SL-325, including receptor occupancy and safety data.
• There is inherent risk associated with the design and progression of planned Phase 2 clinical trials for SL-325, as clinical trials can fail or be delayed, impacting the company's valuation.

Future Outlook

The future outlook for Shattuck Labs is closely tied to the advancement of its SL-325 program. The exercisability of the warrants indicates a future focus on publicly announcing data from the Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the subsequent design of planned Phase 2 clinical trial(s).

Industry Context

Insider purchases, particularly by a Chief Financial Officer in a private placement, are generally viewed as a positive signal of management's belief in the company's valuation and future prospects. This is especially relevant in the biotechnology sector, where capital raises and R&D milestones are critical drivers of value and investor sentiment.

Related Party Transactions

• Andrew R. Neill, the Chief Financial Officer of Shattuck Labs, Inc., participated in a private placement with the company, acquiring shares and warrants. This transaction is considered a related party dealing due to his executive position.

Stakeholder Impact

• Shareholders: May experience increased confidence due to insider buying, but also potential dilution from the private placement and future value tied to SL-325 clinical trial success.
• Employees: Continued funding from the capital raise supports ongoing research and development, potentially securing jobs related to SL-325 development.
• Creditors: Improved financial stability due to the capital raise could enhance the company's ability to meet its obligations.

Next Steps

• Public announcement of data from the single ascending dose and multiple ascending dose portions of the Phase 1 clinical trial of SL-325.
• Public announcement of receptor occupancy and safety data for SL-325.
• Public announcement of the design of planned Phase 2 clinical trial(s) for SL-325.

Key Dates

Recommendation

While the insider purchase by the CFO is a positive signal of confidence, the company's valuation remains heavily dependent on the successful progression of its clinical pipeline, specifically the SL-325 program. The private placement provides capital, but the long-term investment thesis hinges on future clinical trial data. Investors should hold and monitor upcoming clinical trial announcements for SL-325 before making further investment decisions.

Keywords

Shattuck Labs, STTK, Form 4, Insider Trading, Private Placement, Warrants, Common Stock, Andrew R. Neill, CFO, Biotechnology, Clinical Trials, SL-325